Geen internetverbinding — de opgeslagen versie van de pagina wordt getoond.

Amgen Inc

USUSD
← Naar de Screener

Amgen Inc (XETRA:AMG) — Biotechnology: Biological Products (No Diagnostic Substances). Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 4. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.

Over het Bedrijf

Website
amgen.com
Beleggersrelaties
investors.amgen.com/
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hoofdkantoor
Thousand Oaks, United States
CEO
Robert A. Bradway
Werknemers
17 900
Opgericht
1980
Beursgenoteerd Sinds
17.11.1998 (XETRA:AMG)
Uitstaande Aandelen
540.63 mln. per 2026-07-30
Free Float
539.16 mln.
Marktkapitalisatie
226.05 mld. USD
Insiders
0.23%
Institutionele Beleggers
85.02%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
Rechtsvorm
XTIQ
ISIN
US0311621009
LEI
62QBXGPJ34PQ72Z12S66
Uitkeringsratio
60.4%
FCF
10.2 mld. USD
52%
Schuld
57.3 mld. USD
4.3 jr FCF
Dividendreeks
15 jr
Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

advertentie

Beurzen en Tickers

BeursTickerValutaPrijsType
US USA StocksAMGN primairUSD414.87 +1.82%gewone aandelen
HK Hong Kong Stock Exchange4332 secundairHKD—
LSE London Stock Exchange0R0T IOBUSD411.854 +1.17%gewone aandelen
MX Mexican Stock ExchangeAMGN secundairMXN7 500.0098 +0.00%gewone aandelen
XETRA XetraAMG secundairEUR367.95 -1.39%gewone aandelen

Koers over 3 Maanden

stijgingsdag dalingsdag ex-dividenddatum betaaldatumBeweeg over / tik op een dag — openings-, slot-, hoogste en laagste koers

Dividenden

Per jaar, US:AMGN: 9.94 USD (4 uitk.)

Amgen Inc (AMGN) betaalt elk kwartaal dividend uit. Per jaar (12 maanden tot en met de laatst aangekondigde betaling): 9.94 USD per aandeel (betalingen: 4). Dat is ongeveer 2.40% van de huidige aandelenkoers. Op basis van de betalingsgeschiedenis wordt de volgende ex-dividenddatum verwacht rond 20.11.2026. Ononderbroken dividendgeschiedenis: 15 jaar.

Ex-DatumUitbetalingBedrag%TypeTicker
2026-08-212026-09-112.5200 USD0.6/2.4 %per kwartaalUS:AMGN
2026-05-152026-06-052.5200 USD0.6/2.4 %per kwartaalUS:AMGN
2026-02-132026-03-062.5200 USD0.6/2.3 %per kwartaalUS:AMGN
2025-11-212025-12-122.3800 USD0.6/2.3 %per kwartaalUS:AMGN
2025-08-222025-09-122.3800 USD0.6/2.3 %per kwartaalUS:AMGN
2025-05-162025-06-062.3800 USD0.6/2.2 %per kwartaalUS:AMGN
2025-02-142025-03-072.3800 USD0.6/2.2 %per kwartaalUS:AMGN
2024-11-182024-12-092.2500 USD0.5/≈2.2 %per kwartaalUS:AMGN
2024-08-162024-09-062.2500 USD0.5/≈2.2 %per kwartaalUS:AMGN
2024-05-162024-06-072.2500 USD0.5/≈2.2 %per kwartaalUS:AMGN

Grootste Aandeelhouders

HouderBelangAandelenRapportdatum
Blackrock Inc.9.13%49.36 mln.2026-06-30
Vanguard Capital Managem…6.52%35.25 mln.2026-06-30
State Street Corporation5.65%30.56 mln.2026-06-30
Capital World Investors5.38%29.08 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%17.13 mln.2026-06-30
Invesco Ltd.3.02%16.32 mln.2026-06-30
Geode Capital Management…2.9%15.7 mln.2026-06-30
Charles Schwab Investmen…2.78%15.03 mln.2026-06-30
Vanguard Portfolio Manag…2.75%14.85 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%13.99 mln.2026-06-30
Morgan Stanley2.53%13.65 mln.2026-06-30
Invesco QQQ Trust, Serie…2.15%11.61 mln.2026-08-31
SCHWAB STRATEGIC TRUST-S…1.81%9.79 mln.2026-05-31
Income Fund of America1.44%7.76 mln.2026-06-30
iShares Trust-iShares Co…1.35%7.28 mln.2026-07-31
Wells Fargo & Company1.34%7.24 mln.2026-06-30
AMERICAN BALANCED FUND1.31%7.09 mln.2026-06-30
Fidelity Concord Street…1.29%6.98 mln.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%6.6 mln.2026-08-31
WASHINGTON MUTUAL INVEST…1.16%6.27 mln.2026-06-30
BRADWAY ROBERT A (Chief…≈0.12%657 2992026-05-05
SANTOS ESTEBAN (Officer)≈0.02%84 2792026-05-05
GORDON MURDO (Officer)≈0.01%51 8372026-05-05
GRIFFITH PETER H. (Chief…≈0.01%50 7062026-05-05
REESE DAVID M. (Chief Te…≈0.01%42 8122026-05-05
GRAHAM JONATHAN P (Gener…≈0.01%40 2112026-05-05
BRADNER JAMES E. (Office…≈0.01%30 4622026-05-05
ECKERT ROBERT ANDREW (Di…≈0%26 2512026-05-19
JACKS TYLER (Director)≈0%18 2842026-05-19
KULLMAN ELLEN JAMISON (D…≈0%14 5362026-05-19